Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12-16, 2026 in Padua, Italy. AEPC, founded in 1963, is the world’s largest association in congenital cardiology, with over 1,000 specialists from 32 European countries and beyond. This year’s meeting is hosted by the University of Padova and features a scientific program centered on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint is driving clinical progress.
Ventripoint will exhibit alongside its European distributor, AngioPro, focusing on the VMS+™ system’s ability to track cardiac function over time in congenital heart disease (CHD) patients. This approach aligns with the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as key for longitudinal ventricular function assessment (Baumgartner et al., European Heart Journal, 2021).
Ventripoint’s priority for 2026 is accelerating integration of VMS+™ into routine practice. The latest release, VMS+™ 4.0, was built to streamline workflows and reduce assessment time, making advanced cardiac analysis accessible at the point of care. At a patient’s first echocardiogram, VMS+™ provides volumetric measurements equivalent to MRI, supporting clinical decision-making across a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint is an industry leader in applying AI to echocardiography. Its VMS+™ product family, powered by proprietary KBR technology, delivers MRI-equivalent measurements. VMS+™ is compatible with all major ultrasound systems and holds regulatory approvals in the U.S., Europe, and Canada.
